Jasper Therapeutics, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Financial statements are unaudited. Jasper is a clinical-stage biotechnology company developing therapies for hematopoietic stem cell transplantation and related applications. It has no approved products and has generated no product revenue.
Key financial results
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $8.1 million | $5.2 million | $16.3 million | $9.6 million |
| General and administrative expense | $3.8 million | $3.3 million | $8.4 million | $5.1 million |
| Total operating expenses | $12.0 million | $8.4 million | $24.7 million | $14.7 million |
| Net loss | $10.4 million | $8.4 million | $12.6 million | $18.2 million |
| Net loss per share, basic and diluted | $0.29 | $4.00 | $0.35 | $8.89 |
| Net cash used in operating activities | Not reported by quarter in the provided text | $23.6 million | $12.0 million |
Amounts are shown as losses where applicable. Profit margins are not meaningful because the company has no product revenue.
Financial position and material changes
- At June 30, 2022, cash and cash equivalents were $60.8 million, down from $84.7 million at December 31, 2021. Cash, cash equivalents and restricted cash totaled $61.2 million.
- Total current assets were $63.3 million and current liabilities were $6.6 million. Total liabilities were $11.6 million; the company reported no outstanding debt.
- Accumulated deficit was $80.1 million, compared with $67.5 million at year-end 2021. Stockholders’ equity was $58.8 million.
- Six-month operating cash use increased to $23.6 million from $12.0 million year over year. Investing cash use was $0.3 million; financing provided less than $0.1 million. Cash and restricted cash decreased $23.8 million during the period.
- Operating expenses rose 42% in Q2 and 69% for the first six months, principally reflecting higher R&D spending, added personnel, clinical and development activity, laboratory and facility costs, and public-company expenses.
- Six-month net loss declined year over year despite higher operating expenses, largely because of $12.1 million in non-cash gains from changes in the fair values of warrant and earnout liabilities. Those gains do not represent operating cash generation.
Outlook, commentary and risks
- Going concern: Management stated that available cash is not sufficient to support the company for at least one year from the financial statements’ issuance date. The filing says this raises substantial doubt about Jasper’s ability to continue as a going concern. The company expects to seek additional capital through equity or debt financings, alliances, or licensing; availability is not assured. Failure to obtain funding could require delays, reductions, or discontinuation of programs.
- Development plans: Jasper planned to initiate a registrational JSP191 study in AML patients undergoing stem cell transplantation by the end of Q1 2023 and expected to begin a lower-risk MDS pilot study in H2 2022. It also expected to complete enrollment in its SCID Phase 1/2 trial by mid-2023. These are management plans, not assurances of timing or outcome.
- Clinical commentary: The company reported preliminary results including donor-cell engraftment in seven of ten SCID patients in a specified cohort, and successful primary engraftment in all 24 patients in initial MDS/AML trial results. It reported no JSP191 treatment-related serious adverse events to date in those studies. The filing cautions that early and interim results may change and may not predict later results.
- Key risks: Product candidates remain investigational; clinical, regulatory, manufacturing, enrollment, and commercialization outcomes are uncertain. Jasper relies on third parties for trials and manufacturing, including a single-source supplier for clinical product supply. COVID-19 may disrupt enrollment, sites, suppliers, or timelines; geopolitical events, inflation, and capital-market volatility may affect costs, supply, and access to financing.
- Other items: Jasper terminated its non-exclusive Aruvant collaboration in July 2022 after Aruvant discontinued development of its SCD gene therapy. The company reported no material legal proceedings and stated that disclosure controls were effective at quarter-end.
Investor verification priorities
- Confirm the timing, amount, and terms of additional financing, given the explicit going-concern warning and accelerating operating cash use.
- Track quarterly cash burn and clinical spending against the $60.8 million cash balance; the filing does not provide a clear cash-runway estimate.
- Verify progress and timing for the planned AML registrational study, lower-risk MDS pilot, and SCID enrollment milestone.
- Review full clinical datasets and safety follow-up, rather than relying on preliminary results, and assess whether findings are replicated in larger studies.
- Assess manufacturing continuity and dependence on Lonza and other external providers, along with potential dilution from outstanding options, warrants, and equity plans.